Table 3.
Treatment costs (in 2020 euros [€]) over 12 months
| Cost element | [177Lu]Lu-DOTA-TATE | Everolimus | Sunitinib | |
|---|---|---|---|---|
| Originator | Generic | |||
| Costs per 12 months (€) | ||||
| Drug acquisitiona | 74 000 | 41 587 | 24 995 | 47 517 |
| Drug administration | NA | NA | NA | |
| If hospitalisation < 1 day | 1412 | NA | NA | NA |
| If hospitalisation > 1 day (base case) | 5884 | NA | NA | NA |
| Supportive treatment with SSA | 10 635 | 13 184 | 13 184 | 13 184 |
| PanNETs | ||||
| Management of AEs (€) | 54 | 156 | 156 | 137 |
| Total cost (€) (base case) | 90 519 | 54 772 | 38 180 | 60 701 |
| Median PFS (months) | 30.3 | 11.0 | 11.0 | 11.4 |
| Total cost per month of PFS (€) | 2989 | 4975 | 3472 | 5337 |
| GI-NETs | ||||
| Management of AEs (€) | 54 | 168 | 168 | NA |
| Total cost (€) | 90 519 | 54 772 | 38 180 | |
| Median PFS (months) | 28.4 | 11.0 | 11.0 | |
| Total cost per month of PFS (€) | 3189 | 4990 | 3483 | |
aCosts for study drug
AE adverse event, GI-NET gastrointestinal neuroendocrine tumours, NA not applicable, PanNET pancreatic neuroendocrine tumour, PFS progression-free survival, SSA somatostatin analogs